A study currently underway aims to learn more about the impact of an “investigational gene therapy” for adults who have geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). GA affects central vision and can lead to progressive, permanent vision loss. The PARASOL Geographic Atrophy Study, being conducted by Janssen Research & Development LLC, investigates the safety and efficacy of gene therapy in the treatment of GA. Study participants need to be age 60 or older and have GA caused by AMD. Additional criteria for eligibility apply as well. To learn more about the condition or details about eligibility, visit the webpage for the PARASOL Geographic Atrophy Study.
Recent Posts
- RDPFS Awards Grant to Hadley: Workshops to Support the Microsoft Seeing AI App
- RDPFS Awards Grant to The Chicago Lighthouse: IT Services Development Initiative—Expansion and Replication
- New Blind Doll Increases Representation of People Who Are Visually Impaired
- Research Update: Potential New Treatment for Diabetic Retinopathy Could Address the Disease Much Earlier
- Major Accessibility Website Set to Close by End of August: Users Encouraged to Save Archived Material
Recent Comments
No comments to show.